The place of high-dose therapy with haemopoietic stem cell transplantation in relapsed and refractory Hodgkin's disease
Authors:
- 1 March 1993
- journal article
- review article
- Published by Elsevier in Annals of Oncology
- Vol. 4 (suppl_1) , S21-S27
Abstract
Conventional salvage therapy in Hodgkin's disease is appropriate in patients who relapse after a first complete remission of greater than one year many of whom who will have good long term survival with no further therapy. Patients who do not achieve CR, who relapse within one year of CR1 or who have a second relapse will have a survival of less than 20% at 5 years and these patients are candidates for high dose therapy (HDT) and Autologous Bone Marrow Transplantation (ABMT) or a second line salvage protocol. Current published and registry data suggests that HDT and ABMT may be superior and there is data from one prospective randomised trial to support this view. The best practice of ABMT to be used in this context must be decided after consideration of; timing, status, source of haematological stem cells, use of haematopoietic growth factors (HGF's) and dose and scheduling of high dose therapy. Confirmatory randomised trials are still urgently required before the optimal strategy for the management of relapsed Hodgkin's disease is defined.Keywords
This publication has 33 references indexed in Scilit:
- Chemotherapy of Advanced Hodgkin's Disease with MOPP, ABVD, or MOPP Alternating with ABVDNew England Journal of Medicine, 1992
- Salvage chemotherapy in Hodgkin's diseaseAnnals of Oncology, 1990
- Phase II study of moplace chemotherapy for patients with previously treated Hodgkin's disease: A calgb studyMedical and Pediatric Oncology, 1990
- Successful treatment of refractory Hodgkin's disease by high-dose combination chemotherapy and autologous bone marrow transplantationBlood, 1989
- High-dose chemotherapy with autologous bone marrow transplantation in 50 advanced resistant Hodgkin's disease patients: an Italian study group report.Journal of Clinical Oncology, 1988
- MIME chemotherapy (methyl-GAG, ifosfamide, methotrexate, etoposide) as treatment for recurrent Hodgkin's disease.Journal of Clinical Oncology, 1987
- High dose chemotherapy and autologous bone marrow transplantation in refractory Hodgkin's diseaseBritish Journal of Cancer, 1986
- Alternating Non-Cross-Resistant Combination Chemotherapy or MOPP in Stage IV Hodgkin's DiseaseAnnals of Internal Medicine, 1986
- High-Dose Cyclophosphamide, Carmustine, and Etoposide and Autologous Bone Marrow Transplantation for Relapsed Hodgkin's DiseaseAnnals of Internal Medicine, 1986
- Successful engraftment of cryopreserved autologous bone marrow in patients with malignant lymphomaBlood, 1978